NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT01507506 2026-04-14
SPECTRO GLIO
Institut Claudius Regaud
Phase 3 Terminated
NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03919071 2026-04-13
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06344130 2026-04-09
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT06934889 2026-03-30
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03197506 2026-03-25
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting